The innate immune system in atherosclerosis - II
Completed
- Conditions
- arterial wall thickeningatherosclerosis10003216
- Registration Number
- NL-OMON42376
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 340
Inclusion Criteria
patients:
- aged 18 years or older
- diagnosis of a known lipid disorder (including but not limited to hypercholestoremia, hypertriglyceridemia, combined hyperlipidemia, hypoalphalipoprotenemia, hypobetalipoprotenemia);Control group:
- Age >18 years
- No previous cardiovascular events
- No medication use
Exclusion Criteria
Both groups:
- Known malignant disorders or any clinically significant medical condition that could interfere with the conduct of the study in the opinion of the investigator.
- Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.
- History of cardiovascular event within the last 3 months
- Clinical signs of acute infection
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>- the expression of pro-atherogenic surface markers on monocytes<br /><br>- gene expression of genes involved in lipid processing</p><br>
- Secondary Outcome Measures
Name Time Method <p>- Trans endothelial migration w<br /><br>- Lipid accumulation in monocytes<br /><br>- In vitro cytokine production<br /><br>- Epigenetic changes </p><br>